19 results on '"Owen, Andrew"'
Search Results
2. The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases
3. Prospects for Long-Acting Treatments for Hepatitis C
4. Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment
5. A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm
6. Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study
7. Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial
8. Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy
9. Association of a Single-Nucleotide Polymorphism in the Pregnane X Receptor (PXR 63396C→T) with Reduced Concentrations of Unboosted Atazanavir
10. Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments
11. Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm.
12. LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases.
13. Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments.
14. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C(right arrow)T) with reduced concentrations of unboosted atazanavir
15. Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals
16. Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals.
17. Predictors of Kidney Tubular Dysfunction in HIV‐Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
18. Association of a Single‐Nucleotide Polymorphism in the Pregnane X Receptor (PXR63396C→T) with Reduced Concentrations of Unboosted Atazanavir
19. Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.